S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Emergency department visits are "high" and "very high" for flu and RSV, respectively, and "elevated" for COVID-19 across the U.S., according to the CDC. As of the week ending Jan. 4, 18.6% of ...

Af­ter see­ing its Covid-19 drug fail in a Phase 3 tri­al last year, Sh­iono­gi on Thurs­day won a $375 mil­lion award from HHS to de­vel­op … ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...

Respiratory syncytial virus (RSV) causes cold-like symptoms in most people but can cause more serious problems in some, especially babies and older adults. Almost all children get RSV at least once by ...

Winter also marks the height of the respiratory virus season, a period of sniffles, sneezes, congestion, fever and other maladies brought about primarily by four pathogens: the respiratory syncytial ...